| Literature DB >> 31221113 |
Dan Lin1, Chun-Yang Zhang2, Zi-Kai He2, Xiao-Dong Zhao2.
Abstract
BACKGROUND: Socially disadvantaged groups, such as drug users, sex workers and homeless individuals, are labelled as "hard-to-reach" (HTR) in public health and medical research. HIV disproportionately impacts these populations, but data on how the HTR status could affect antiretroviral therapy (ART) adherence among HIV-positive people are limited and have not been previously synthesized in a systematic manner. We performed a meta-analysis to explore the association between HTR status and optimal antiretroviral therapy adherence in the HIV-infected population to provide evidence and recommendations regarding ART adherence improvement and HIV infection control and prevention among HTR people.Entities:
Keywords: Adherence; Antiretroviral therapy; HIV; Hard-to-reach population; Meta-analysis
Mesh:
Substances:
Year: 2019 PMID: 31221113 PMCID: PMC6587270 DOI: 10.1186/s12889-019-7135-0
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1PRISMA flow diagram for the meta-analysis
Characteristics of studies included in this meta-analysis
| Author | Publication year | Study period | Region/Country | Study design | Population description | HTR status | Adherence threshold (%) | Adherence measure | Observation period | Quality assessment |
|---|---|---|---|---|---|---|---|---|---|---|
| Aloisi MS [ | 2002 | 1997–1999 | Italy | Cohort | HIV-infected subjects who had never received antiretroviral therapy | DU | 100 | SR | 6 months | Moderate |
| Avery AK [ | 2013 | 2008–2011 | USA | Cross- sectional | Participants who were previously diagnosed HIV+ | HL | 90 | SR | 1 week | High |
| Biello KB [ | 2016 | 2012 | Latin America | Cross- sectional | Men who have sex with men who reported being paid for sex with another man in the past year | SW | 100 | SR | 1 month | Moderate |
| Bijker R [ | 2017 | 2007–2013 | Asia | Cohort | HIV-infected adults starting first-line ART | DU | 95 | SR | 6 months | High |
| Braitstein P [ | 2006 | 1996–2000 | Canada | Cohort | Individuals used triple combination ART as their first HIV therapy and had documented HCV serology | DU | 95 | PR | 1 year | High |
| Cohn SE [ | 2008 | 2002–2005 | USA | Cohort | HIV-infected women between 20 and 34 weeks’ gestation | DU | 100 | SR | 4 days or 3 months | Moderate |
| Cohn SE [ | 2011 | 1997–1999 | USA | Cross- sectional | HIV-infected subjects without prior | DU | 100 | SR | 2 days | High |
| de Boni RB [ | 2016 | 2012–2013 | Argentina, Brazil, Chile, Honduras, Mexico, and Peru | Cross- sectional | Individuals receiving care at HIV clinics | DU | 100 | SR | 1 week | High |
| de Jong BC [ | 2005 | 2001 | USA | Cross- sectional | Patients within a public health care system for HIV/AIDS | DU | 100 | SR | 4 weeks | High |
| Duff PK [ | 2017 | 2014–2017 | Canada | Cohort | Women living with HIV | DU | 95 | SR | 3 to 4 weeks | High |
| Gebo KA [ | 2003 | 1999–2000 | USA | Cross- sectional | Consecutive HIV-infected patients taking at least 1 antiretroviral medication | DU | 90 | SR | 2 weeks | Moderate |
| Gordillo V [ | 1999 | 1997–1998 | Spain | Cross- sectional | HIV-infected patients who were on treatment with antiretroviral drugs | DU | 90 | SR and pill count | 1 week | High |
| Hicks PL [ | 2007 | 2003 | USA | Cross- sectional | HIV patients on HAART in primary care | DU | 95 | SR | 2 weeks | Moderate |
| Jin H [ | 2018 | 2013–2017 | USA | Cross- sectional | HIV-positive men who have sex with men who had biologically confirmed, recent methamphetamine use | HL | 90 | SR | 1 month | Moderate |
| Johnson MO [ | 2003 | 2000–2002 | USA | Cross- sectional | HIV-positive adults taking ART | DU, HL | 90 | SR | 3 days | Moderate |
| Joseph B [ | 2015 | 1996–2012 | Canada | Cohort | HIV-infected people who use illicit drugs in a setting of universal no-cost HIV/AIDS treatment | HL, DU, SW | 95 | PR | 6 months | High |
| King RM [ | 2012 | 2007–2009 | USA | Cross- sectional | Persons living with HIV/AIDS who smoke | DU | 100 | SR | 4 days | Moderate |
| Krusi A [ | 2010 | 1996–2007 | Canada | Cohort | HIV-positive injection drug users | DU | 95 | PR | 6 months | High |
| Mohanned H [ | 2004 | 1999–2001 | USA | Cohort | Convenience sample of HIV-infected subjects seen at outpatient HIV clinics | DU | 100 | SR | 1 week | High |
| O’Neil CR [ | 2012 | 2007–2010 | Canada | Cohort | HIV-positive persons who have accessed antiretroviral therapy | DU | 95 | PR | 1 year | High |
| Palepu A [ | 2004 | 1997–2002 | Canada | Cohort | Participants who were HIV-infected, naive to HAART and who were prescribed treatment | DU | 100 | PR | 6 months | High |
| Roux P [ | 2011 | 2006–2008 | France | Cohort | HIV/HCV coinfected patients on ART | DU | 100 | SR | 4 days | Moderate |
| Shannon K [ | 2005 | 2002–2004 | Canada | Cohort | HIV-infected persons | DU | 95 | PR | 6 months | Moderate |
| Sharpe TT [ | 2004 | 1997–2000 | USA | Cross- sectional | HIV-infected women | DU | 100 | SR | not reported | Moderate |
| Stone VE [ | 2001 | 1993–1995 | USA | Cross- sectional | Women living with HIV | DU | 100 | SR | 3 days | Moderate |
| Teixeira C [ | 2013 | 2006–2008 | Brazil | Cohort | HIV-positive patients with no previous ART | DU | 95 | SR | 1 month | High |
| Tucker JS [ | 2003 | 1997–1998 | USA | Cohort | People with known HIV infection and made at least one patient care visit | DU | 100 | SR | 1 week | High |
| Turner BJ [ | 2000 | 1993–1997 | USA | Cohort | Postpartum HIV-infected women | DU | 80 | PR | > 2 months | High |
| Wilson TE [ | 2002 | 1998–1999 | USA | Cohort | HIV-positive women | DU | 95 | SR | 6 months | Moderate |
Abbreviations: HTR hard-to-reach, DU drug users, HL homelessness, SW sex workers, SR self-reporting, PR pharmacy refills
Fig. 2Pooled odds ratio for optimal ART adherence by HTR populations
Odds ratios describing the association between HTR status and optimal ART adherence, categorized by subgroups
| Subgroup | Number of measures of correlation | OR | 95% CI | Tests for heterogeneity | Tests for interaction | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | OR | 95% CI | ||||||||
| Study design | ||||||||||
| Cohort | 18 | 0.54 | 0.45 | 0.65 | 0.00 | 58.3 | 0.98 | 0.77 | 1.25 | 0.88 |
| Cross-sectional | 14 | 0.55 | 0.47 | 0.64 | 0.00 | 31.4 | ||||
| Adherence threshold/cut-off point (%) | ||||||||||
| 100 | 13 | 0.56 | 0.46 | 0.67 | 0.00 | 52.1 | – | |||
| ≥ 95 | 12 | 0.52 | 0.42 | 0.66 | 0.00 | 54.1 | ||||
| < 95 | 7 | 0.55 | 0.43 | 0.71 | 0.00 | 47.9 | ||||
| Adherence measure | ||||||||||
| Self-reporting | 22 | 0.56 | 0.49 | 0.64 | 0.00 | 42.2 | – | |||
| Pharmacy refill | 9 | 0.47 | 0.35 | 0.64 | 0.00 | 64.1 | ||||
| Self-reporting & pill count | 1 | 0.72 | 0.53 | 0.97 | 0.03 | – | ||||
| Region/country | ||||||||||
| USA | 16 | 0.58 | 0.50 | 0.68 | 0.00 | 38.5 | – | |||
| Canada | 9 | 0.44 | 0.34 | 0.58 | 0.00 | 51.7 | ||||
| Others | 7 | 0.60 | 0.47 | 0.78 | 0.00 | 58.5 | ||||
| Observational period | ||||||||||
| ≥ 6 months | 11 | 0.44 | 0.35 | 0.56 | 0.00 | 44.3 | 0.72 | 0.55 | 0.94 | 0.02 |
| < 6 months | 21 | 0.61 | 0.53 | 0.69 | 0.00 | 41.5 | ||||
| Quality assessment results | ||||||||||
| High | 18 | 0.57 | 0.48 | 0.67 | 0.00 | 53.2 | 1.1 | 0.85 | 1.42 | 0.48 |
| Moderate | 14 | 0.52 | 0.44 | 0.65 | 0.00 | 41.3 | ||||
The number of studies was 29, but the number of measures of correlation was 32